102O Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1–positive locally advanced/m…

Overview of attention for article published in Annals of Oncology, April 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (87th percentile)
Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

news: 1 news outlet
twitter: 9 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 89 Mendeley

So far, Altmetric has seen 10 X posts from 9 X users, with an upper bound of 114,524 followers.

RT @GlopesMd: "With an additional 6 mo follow-up, pembro demonstrated continued OS benefit vs chemo as first-line therapy in pts with local…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 6 additional X posts.